Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 15 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 7.5 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 2.5 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 5 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - bortezomib 3.5mg (as a mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib-aft, in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib-aft, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib-aft is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ciclosporin 25mg;   - soft gelatin capsule - 25 mg - active: ciclosporin 25mg   excipient: corn oil dl-alpha tocopherol ethanol gelatin glycerol iron oxide black polyethylene glycol hydrogenated castor oil propylene glycol   titanium dioxide - solid organ transplantation prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allogeneic transplantations. treatment of transplant rejection in patients previously receiving other immunosuppressive agents. bone marrow transplantation prevention of graft rejection following bone marrow transplantation. prevention or treatment of graft-versus-host disease (gvhd).

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - ciclosporin 25mg - soft gelatin capsule - 25 mg - active: ciclosporin 25mg excipient: ethyl lactate gelatin glycerol iron oxide black lecithin medium-chain triglycerides peg-40 castor oil polysorbate 20 purified water sorbitan oleate titanium dioxide - solid organ transplantation: - prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allergenic transplantations. - treatment of transplant rejection in patients previously receiving other immunosuppressive agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - azathioprine 25mg - film coated tablet - 25 mg - active: azathioprine 25mg excipient: lactose monohydrate magnesium stearate maize starch opadry orange 06b230003 starch stearic acid - imuran is used as an immunosuppressant antimetabolite, either alone or, more commonly in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ruxolitinib phosphate 19.8mg equivalent to ruxolitinib 15 mg;   - tablet - 15 mg - active: ruxolitinib phosphate 19.8mg equivalent to ruxolitinib 15 mg   excipient: colloidal silicon dioxide hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium starch glycolate - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ruxolitinib phosphate 6.6mg equivalent to ruxolitinib 5 mg;   - tablet - 5 mg - active: ruxolitinib phosphate 6.6mg equivalent to ruxolitinib 5 mg   excipient: colloidal silicon dioxide hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium starch glycolate - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.